Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
RV

NASDAQ · RVMD

Revolution Medicines, Inc.

Healthcare · Biotechnology

$191.31

Up+$1.04 (+0.55%)

Updated Nov 2, 2026, 10:14 AM

SID Score

6.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
15.18B
P/E ratio
-15.46
Dividend yield
0.00%
52-week range
$58.00 – $224.31
Volume
1.1M
Avg. volume
2.27M

Price performance · RVMD

RVMD price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

RVMD closed at $191.31 after 20 trading sessions, down 7.88% for the selected period.

Last close
$191.31
Period change
-7.88%
Period low
$177.96
Period high
$207.68
Daily close
View OHLC price history
RVMD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$188.38$192.75$187.2775$191.311.1M
Oct 29, 2026$187.38$192.00$187.37$190.271.32M
Oct 28, 2026$185.08$188.85$183.855$188.72890.43K
Oct 27, 2026$182.68$187.655$181.20$186.221.17M
Oct 26, 2026$186.99$188.30$181.00$183.901.66M
Oct 23, 2026$187.59$189.52$183.61$186.991.72M
Oct 22, 2026$192.06$194.59$185.34$187.691.49M
Oct 21, 2026$198.71$203.49$193.97$194.281.88M
Oct 20, 2026$181.50$197.14$180.00$196.552.74M
Oct 19, 2026$179.98$183.87$177.00$182.151.98M
Oct 16, 2026$188.86$189.68$175.91$177.962.97M
Oct 15, 2026$193.31$195.94$189.14$189.261.57M
Oct 14, 2026$186.84$197.00$185.8801$193.522.46M
Oct 13, 2026$191.57$193.61$187.14$188.442.94M
Oct 12, 2026$187.79$194.26$184.76$193.951.67M
Oct 9, 2026$186.01$193.50$184.3701$189.762.21M
Oct 8, 2026$198.51$199.64$180.49$188.124.86M
Oct 7, 2026$198.18$203.50$196.25$200.871.19M
Oct 6, 2026$208.57$208.57$195.00$199.871.63M
Oct 5, 2026$207.68$210.27$201.83$207.681.42M

Latest RVMD news

The latest Smart Investors Daily articles mentioning RVMD.

Stock researchCompany · Overview

RVMD research

Overview

Company profile and research snapshot.

Company profile

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$82.00
Implied upside
—
Analysts
—
RVMD recent ratings
DateFirmRatingTarget
Oct 21, 2026TD CowenBuy—
Oct 19, 2026Truist SecuritiesBuy—
Oct 16, 2026William BlairOutperform—
Oct 15, 2026NeedhamBuy—
Oct 14, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"

Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By